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Abstract
One of the most fundamental challenges in developing treatments for autism-spectrum disorders is 
the heterogeneity of the condition. More than one hundred genetic mutations confer high risk for 
autism, with each individual mutation accounting for only a small fraction of autism cases1–3. 
Subsets of risk genes can be grouped into functionally-related pathways, most prominently 
synaptic proteins, translational regulation, and chromatin modifications. To possibly circumvent 
this genetic complexity, recent therapeutic strategies have focused on the neuropeptides oxytocin 
and vasopressin4–6 which regulate aspects of social behavior in mammals7. However, whether 
genetic risk factors might predispose to autism due to modification of oxytocinergic signaling 
remains largely unknown. Here, we report that an autism-associated mutation in the synaptic 
adhesion molecule neuroligin-3 (Nlgn3) results in impaired oxytocin signaling in dopaminergic 
neurons and in altered social novelty responses in mice. Surprisingly, loss of Nlgn3 is 
accompanied by a disruption of translation homeostasis in the ventral tegmental area. Treatment of 
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Nlgn3KO mice with a novel, highly specific, brain-penetrant inhibitor of MAP-kinase interacting 
kinases resets mRNA translation and restores oxytocin and social novelty responses. Thus, this 
work identifies an unexpected convergence between the genetic autism risk factor Nlgn3, 
translational regulation, and oxytocinergic signaling. Focus on such common core plasticity 
elements might provide a pragmatic approach to reduce the heterogeneity of autism. Ultimately, 
this would allow for mechanism-based stratification of patient populations to increase the success 
of therapeutic interventions.
Social recognition and communication are critical elements in the establishment and 
maintenance of social relationships. Oxytocin and vasopressin are two evolutionarily 
conserved neuropeptides with important functions in the control of social behaviors, in 
particular pair-bonding and social recognition7,8. In humans, genetic variation of the 
oxytocin receptor gene (Oxtr) is linked to individual differences in social behavior9. 
Consequently, signaling modulators and biomarkers for the oxytocin/vasopressin system are 
being explored for conditions with altered social interactions such as autism spectrum 
disorders (ASD)5,6. In mice, mutation of the genes encoding oxytocin or its receptor results 
in a loss of social recognition and social reward signaling10–14. Mutation of Cntnap2, a gene 
linked to ASD in humans, results in reduced oxytocin levels in mice, and elevation of 
oxytocin rescues altered social behavior in this model15. However, the vast majority of 
genetic autism risk factors have no known links to oxytocinergic signaling1–3,16.
Here we explored oxytocin responses in mice which recapitulate a loss of function in the 
autism risk gene Nlgn3 17–19 . Nlgn3 encodes a synaptic adhesion molecule20–23 and Nlgn3 
mutant mice exhibit a range of behavioral alterations, including motor stereotypies23,24, 
alterations in social novelty preference25–28 (but see29,30), social reward31, and social 
novelty responses31. Despite these alterations in social behaviors, adult Nlgn3KO mice 
exhibit normal responses to inanimate objects26,31. In a five-trial social habituation/
recognition task we observed that the social novelty response phenotype is established 
already in juvenile Nlgn3KO mice (Fig.1a–c, Extended Data Fig. 1a–b, see methods for 
details on the task). The recognition and response to unfamiliar conspecifics depends on 
multiple neural circuit elements, including dopaminergic cells in the ventral tegmental area 
(VTA DA neurons)7,31–33. Re-expression of Nlgn3 selectively in dopaminergic cells restored 
social novelty responses in juvenile Nlgn3KO mice (Fig.1d–f, Extended Data Fig.1c,d). 
Conversely, selective inactivation of Nlgn3 in VTA DA neurons was sufficient to affect 
social novelty responses (Fig. 1g–i, Extended Data Fig.1 e–h). Social recognition in this 
assay depends on oxytocin receptor function, as treatment of wild type mice with the 
oxytocin receptor antagonist L-368,899 impaired recognition (Fig.1j–l, Extended Data Fig. 
1.i,j).
The function of VTA DA neurons in social novelty responses and reinforcement is in part 
dependent on an oxytocin-induced elevation of neuronal firing. Specifically, oxytocin 
released from axons that arise from hypothalamic nuclei increases the firing of VTA DA 
neurons projecting to the nucleus accumbens (NAc) 12,13. Thus, we examined whether loss 
of Nlgn3 might impact the response of this population of neurons to oxytocin. We marked 
VTA DA neurons projecting to the NAc medial shell and performed electrophysiological 
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recordings from back-labeled neurons in acute slices of the VTA (Fig. 1m,n). Consistent 
with previous reports, back-labeled neurons showed low Ih currents, and there was no 
significant difference between genotypes in Ih and other basic biophysical properties 
(Extended Data Fig. 2). In cell attached recordings, baseline firing frequency of VTA DA 
neurons from Nlgn3KO mice was slightly reduced as compared to wild type mice (Fig. 1p). 
Notably, bath application of 1 μM oxytocin significantly increased firing frequency in cells 
from wild type but had no effect in Nlgn3KO slices (Fig. 1o,q). These findings uncover a 
requirement for the autism risk factor Nlgn3 for oxytocin responses in the VTA.
A loss of oxytocinergic neurons has been reported in knock-out mice for the autism risk 
factors Cntnap2 and Shank3b 14,15. In Nlgn3KO mice we did not detect any alteration in the 
density of oxytocinergic neurons in the paraventricular nucleus (one of the major 
oxytocinergic nuclei) or in the density of oxytocinergic fibers in the VTA (Fig. 2a,b, 
Extended Data Fig. 3a–c). Fluorescent in situ hybridization (FISH) revealed a slight increase 
in Oxtr mRNA in VTA DA neurons from Nlgn3KO mice compared to wild type animals 
(Fig. 2c–d, Extended Data Fig. 3d–f). However, targeted proteomics (parallel reaction 
monitoring) on microdissected VTA tissue did not detect significant alterations in total 
oxytocin receptor protein (Extended Data Fig. 3g, vasopressin 1a receptor mRNA and 
protein were unaltered, Extended Data Fig. 3 g–j and Table S1). Thus, we performed shot-
gun proteomics for an unbiased identification of molecular alterations in the VTA of 
Nlgn3KO mice (Extended data Fig.4a–c, Table S2). Gene ontology (GO) and network-based 
functional classification analysis for proteins altered in Nlgn3KO VTA identified protein 
transport, cell adhesion, and mRNA translation as main categories (Extended Data Fig.4b,c). 
Dysregulation of membrane trafficking and GPCR signaling components is consistent with 
the previously discovered roles for Nlgn3 in synapse organization and GPCR 
signaling22,23,34. However, the alterations in regulators of translation were surprising. 
Alterations in mRNA translation have been linked to neuronal plasticity deficits. We 
previously observed that behaviorally-induced plasticity is altered in VTA DA neurons of 
Nlgn3KO mice31. Thus, we compared translation in VTA DA neurons of naïve and 
behaviorally exposed wild type and Nlgn3KO mice. Incorporation of the methionine 
analogue azidohomoalanine (AHA)35 in VTA DA neurons (marked by tyrosine hydroxylase) 
of acute mouse brain slices from naive Nlgn3KO mice was reduced as compared to wild type 
(Fig. 2e–g. and see Extended Data Fig. 4d for data from cortical slice preparations). 
Interestingly, AHA incorporation was elevated in VTA DA neurons from Nlgn3KO mice 
exposed to handling (Fig.2e–g). This suggests a signaling-dependent disruption of 
translation homeostasis in the mutant mice.
Disruption of translation homeostasis is thought to broadly modify neuronal proteins 
resulting in impaired plasticity and neurodevelopmental conditions36–40. Thus, we sought to 
normalize translation in Nlgn3KO mice and to test whether this would restore oxytocin 
responses in VTA DA neurons. We focused on MAP-kinase interacting kinases (MNKs) 
which are critical regulators of signaling-dependent modification of mRNA translation (Fig. 
3a). MNK inhibition was reported to modify ribosomal protein levels and to ameliorate 
behavioral and plasticity alterations in Fmr1 knock-out mice (Fmr1KO)41–43. We tested 
efficacy and brain penetrance of a novel series of highly specific MNK inhibitors originally 
developed for oncology applications44. One of these compounds, ETC-168 resulted in a 
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dose-dependent reduction in phosphorylation of the MNK target eIF4E in cultured cortical 
mouse neurons without affecting eIF4E, eIF4G protein levels or ERK1/2 activity (Fig. 3b, 
Extended Data Fig. 5a–e). In wild type mice, orally administered ETC-168 had significant 
brain penetration (brain to plasma ratio 0.12) with a half-life of 4.3 hrs (Fig. 3d), and 
resulted in a reduction in eIF4E phosphorylation in the VTA and other brain areas (Fig. 3c, 
Extended Data Fig. 5f and l). Of note, phospho- or protein levels of Eif4E or MNK1 are 
unaltered in the VTA of Nlgn3KO mice (Extended Data Fig. 5g–k). As a proof of concept, 
we probed the effectiveness of ETC-168 treatment in modifying a behavioral phenotype in 
Fmr1KO mice. In a place-independent discrimination task, Fmr1KO and wild type mice 
learned a cue-reward contingency rule equally well, but Fmr1KO mice were impaired upon 
contingency reversal (Extended Data Fig. 6a, b). ETC-168 treatment during the reversal 
phase of the task significantly improved their performance (Extended Data Fig. 6c, d). Thus, 
ETC-168 is a novel, highly selective, brain-penetrant inhibitor of MNK1/2 activity, which 
modifies cognitive behavior in mice.
We then asked whether ETC-168 treatment would modify the translational machinery in the 
VTA of Nlgn3KO mice. Using tandem mass tag (TMT)-based isobaric labeling we verified 
the de-regulation of translational machinery in VTA tissue from vehicle-treated Nlgn3KO 
versus vehicle treated wild type mice (Extended Data Fig. 7a–d). Gene set enrichment 
analysis45 uncovered an elevation in core proteins of cytoplasmic but not mitochondrial 
ribosomes (Fig. 3e, Extended Data Fig. 7e, g). MNK-inhibition with ETC-168 abolished the 
increase in core ribosomal proteins in Nlgn3KO VTA (Fig.3f, Extended Data Fig.7f, h). In 
acute slices from ETC-168-treated Nlgn3KO mice, AHA incorporation was significantly 
reduced as compared to vehicle treated Nlgn3KO mice, resulting in AHA incorporation 
levels similar to slices from vehicle treated wild-type mice (Fig.3g–i).
We then tested whether ETC-168 treatment restored oxytocin responses and social novelty 
responses in Nlgn3KO mice (Fig. 4a). Notably, short-term oral treatment (2 applications of 
5mg/kg ETC-168 over 26 hrs) of Nlgn3KO mice recovered the oxytocin-induced elevation of 
firing frequency seen in wild type mice (Fig. 4b, c). This treatment also fully restored social 
novelty responses, with no detectable effect on wild type mice (Fig. 4a, d–f, Extended Data 
Fig. 8). This pharmacologically recovered social recognition behavior was dependent on 
oxytocin receptor function (Extended Data Fig. 9). Importantly, ETC-168 treatment was well 
tolerated and remained effective in a long-term treatment regime (Extended Data Fig. 7a–c, 
and Extended Data Fig. 10). Thus, modification of translation homeostasis in Nlgn3KO mice 
by MNK inhibition restores oxytocin responses and social novelty responses.
This work uncovers an unexpected convergence between the genetic autism risk factor 
Nlgn3, translational regulation, oxytocinergic signaling, and social novelty responses. While 
loss of Nlgn3 impairs oxytocin responses in VTA DA neurons, the behavioral phenotype 
does not fully phenocopy genetic loss of oxytocin. Oxytocin KO mice exhibit impaired 
habituation in the social recognition task10 whereas Nlgn3KO mice habituate normally but 
exhibit a selective deficit in the response to a novel conspecific. This is likely due to 
differential roles of Nlgn3 and oxytocin across multiple neural circuits and over 
development. Moreover, Nlgn3 loss-of-function also impacts signaling through additional G-
protein coupled receptors23.
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We propose that pharmacological inhibition of MNKs may provide a novel therapeutic 
strategy for neurodevelopmental conditions with altered translation homeostasis. 
Importantly, MNK loss-of-function appears to be overall well tolerated. MNK1/2 double-
knock-out mice are viable46 and several novel MNK inhibitors are entering clinical trials for 
cancer therapy47. Previously available MNK-inhibitors were greatly limited by specificity 
and brain penetrance. Our work not only highlights a new class of highly-specific, brain-
penetrant MNK inhibitors but also expands their application from Fragile X41 to a non-
syndromic model of ASD. The common disruption in translational machinery and 
phenotypic rescue in two very different genetic models highlights that genetic heterogeneity 
of ASD might be reduced to a smaller number of cellular core processes. This raises the 
possibility that pharmacological interventions targeting such core processes may benefit 
broader subsets of patient populations.
Methods
Mice
Male wild type, Nlgn3KO 19 and Fmr1KO mice48 were used for this study. Note that this 
strain of Nlgn3KO mice contains a transcriptional stop cassette19 preventing genetic 
compensation events that might be triggered in mutants expressing truncated mRNAs49. For 
dopamine neuron-specific manipulations DAT-Cre BAC transgenic mice were employed50. 
Mice were kept on a C57BL/6j background. All animals were group housed (weaning at P21 
– P23) under a 12h light – dark cycle (6:00 a.m. – 6:00 p.m.) with food and water ad libitum. 
All physiology and behavior experiments were performed during the light cycle. Embryos 
for cortical cultures were obtained from NMRI mice (Janvier). All the procedures performed 
at University of Lausanne and Biozentrum complied with the Swiss National Institutional 
Guidelines on Animal Experimentation and were approved by the respective Swiss Cantonal 
Veterinary Office Committees for Animal Experimentation.
Pharmacokinetics of ETC-168
A group of twenty-seven male C57BL/6 mice were administered with ETC-168 solution 
formulation in 7.5% NMP, 5% Solutol HS, 10% PG, 30% PEG-400, 47.5% Normal Saline at 
a dose of 10 mg/kg. Blood samples (approximately 60μl) were collected under light 
isoflurane anesthesia from retro orbital plexus at PD, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hr. 
Plasma samples were separated by centrifugation of whole blood and stored below −70°C 
until analysis. Immediately after collection of blood, brain samples were collected from each 
mouse at PD, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hr. Brain samples were homogenized using ice-
cold phosphate buffer saline (pH 7.4) and homogenates were stored below −70°C until 
analysis. Total homogenate volume was three times the tissue weight. All samples were 
processed for analysis by protein precipitation using acetonitrile and analyzed with fit-for-
purpose LC/MS/MS method (LLOQ – 2.00 ng/mL in plasma and 1.00 ng/mL in brain). 
Pharmacokinetic parameters were calculated using the non-compartmental analysis tool of 
Phoenix WinNonlin® (Version 6.3).
Hörnberg et al. Page 5














For in vitro experiments, ETC-168 was dissolved in DMSO. For in vivo treatment, ETC-168 
was dissolved in 0.5% Methylcellulose (Sigma, M7140) and 0.1% Tween-80 (Sigma, 
P5188) in MilliQ water to 1.25 mg/ml, and sonicated for 30 min. Animals were gavaged 24h 
and 2h before behavioral assessment or tissue collection for acute treatment. In the chronic 
treatment regime, animals were treated every 24 h and two hours before start of the 
evaluation. The OXTR antagonist L-368,899 (Tocris, #2641) was dissolved in saline and 10 
mg/kg was applied via i.p. injection 2h before the start of behavioural assessments, or 15 
min before the final dose of ETC-168.
Stereotaxic injection
Injections of diluted (1:4) Red Retrobead™ were done at P19-P23 and performed under 
isoflurane anesthesia (Baxter AG, Vienna, Austria). The animals were placed in a stereotaxic 
frame (Kopf Instrument) and a single craniotomy was made over the NAc medial shell at the 
following stereotaxic coordinates: ML 0.55 mm, AP 1.5 mm, DV −4.05 mm from bregma. 
Injections were made with a 30-G Hamilton needle (Hamilton, 7762-03) for a total volume 
of 300 nL. Injection sites were confirmed post-hoc by immunostaining. For 
electrophysiological experiments, the animals were left 5-8 days after injection before the 
start of experiment.
For Nlgn3 conditional knock-down experiments, injections of purified AAV2-DIO-
miRNlgn3-GFP and AAV2-DIO-miR-GFP were performed as described previously31. 
Briefly, DAT-cre transgenic mice were injected at postnatal day 5 – 6 and a single 
craniotomy was made over the VTA at following stereotaxic coordinates: ML +0.15 mm, AP 
+0.2 mm, DV −4.2 mm from lambda for P5-P6. Injections were made with a 33-G Hamilton 
needle (Hamilton, 65460-02) for a total volume of 200 nL. Behavioral testing was performed 
at postnatal day 28 and injections sites were confirmed post-hoc by immunostaining as 
described previously31. Briefly, VTA::DANL3KD mice were included if a minimum of 20% 
of TH-positive cells in the VTA were GFP-positive. Mice were excluded from the analysis if 
their body weight was less than 75% of the body weight at the start of behavioral trials or in 
case post-hoc analysis revealed inefficient or off-target viral infection.
Habituation/novelty recognition task
Social recognition is considered to be commonly affected in individuals on the autism 
spectrum. Autistic individuals perform poorly on face identity recognition tasks, especially 
when a medium to high time delay (seconds to several minutes) between face presentation is 
applied51,52. To model social recognition in juvenile male mice we adopted previous 
protocols that had been developed for adult rodents10,53. In this test, recognition between 
juvenile male mice (postnatal day 26 – 32) was tested with 5 minute inter-trial intervals that 
mimic the timescales of recognition tasks from patient studies. An experimental cage similar 
to the animal’s home cage was used with grid, food, and water removed. The experimental 
animals were acclimated in the cage for 30 min before the start of the test. At the start of the 
first trial, a novel same-sex mouse (stimulus mouse: C57BL/6J juvenile male mice, P21-
P28) or an object (Lego block) was introduced into the cage for 2 min and mice were left to 
freely interact. This was repeated for 4 consecutive trials with 5 min in-between trial 
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intervals to allow habituation to the stimulus mouse or object. On the 5th trial, a novel mouse 
(littermate to the stimulus mouse) or a novel object (dice) was introduced. For the social 
stimulus, interaction was scored when the experimental mouse initiated the action and when 
the nose of the animal was oriented toward the social stimulus mouse only. For the object 
stimulus, interaction was scored when nose of the mouse was oriented 1 cm or less towards 
the object. The interaction time was used to calculate the recognition index as: (Interaction 
trial 5) - (Interaction trial 4). Social recognition in rodents has been reported to depend on 
oxytocin signaling11,54. To pharmacologically validate the recognition task, we treated mice 
with the oxytocin receptor antagonist (L-368,899 10 mg/kg injected intraperitoneally 2 hrs 
before testing). This treatment significantly suppressed recognition of novel conspecifics in 
this task (see Fig.1k,l).
Place-independent cue discrimination and reversal task
Adult male mice were used for this test. The test box (25 × 35 cm) was divided in a waiting 
and a reward zone by a gated plexiglass wall. Reward (condensed milk) was associated to 
one of the two lining patterns of a double tray (white tape vs brown sandpaper). The tray 
was turned in a pseudorandom fashion between trials in order to present the rewarded 
pattern on the right and the left 8 times within a daily session of 16 trials. Sliding lids were 
used to prevent nosepoke in the correct target after the mouse made a wrong choice, and to 
signal end of a trial and return to the waiting zone after the bait has been consumed. Before 
the start of the trial, mice were food deprived overnight and the reward was presented in the 
home cage to habituate to the reward. For the duration of the test, mice were food restricted 
overnight and receive food ad libitum after completion of the discrimination task. After the 
first night of food deprivation, mice were brought to the testing arena where they find 
condensed milk droplets (15 μl) in falcon lids similar to those used for the test. First day of 
habituation takes place in groups of cage mates, second day in individual session. Mice were 
shaped to shuttle to the waiting compartment of the arena after having consumed the reward. 
On day 1, mice were trained to find the reward only in one of two adjacent falcon lids that 
have been lined and mounted on little stages with a different pattern (brown sandpaper vs 
white tape). Each mouse undergoes 16 daily trials, with a cutoff of 20 minutes. Mice not 
completing 16 trials by the third testing day were excluded from further testing. Mice not 
attaining learning criterion for the first contingency (8 consecutive correct responses over 
two days), after 6 days of training did not go to the reversal learning step (nor received any 
treatment). Mice were trained for 6 consecutive days/week. Feeding was restricted to 1 g/
mouse overnight. On day 7 (day 1 of reversal learning training), mice received ETC-168 5 
mg/kg or vehicle by gavage 120 min before starting the tests for the duration of the reversal 
task. For the contingency reversal learning, mice were trained to nosepoke in the previously 
non-baited pattern in order to find reward. The training schedule was the same as before: 16 
trials / day, until attainment of learning criterion (second day when 8 consecutive correct 
responses have been performed).
Open field and marble burying
Male mice were placed individually in the center of a square open field arena (50 × 50 × 30 
cm) made of grey plastic for 7 minutes. Velocity (cm/sec) was analyzed using EthoVision10 
system (Noldus). The arena was cleaned with 70% ethanol between trials. For the marble 
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burying test, animals were placed in a standard Type II cage with 5 cm bedding containing 
20 identical black marbles distributed equally for 30 minutes. A marble was considered 
buried if at least 2/3 of the marble was covered.
Electrophysiology
Male mice (P28-P34) were deeply anesthetized with isoflurane (4% in O2, Vapor, Draeger) 
prior decapitation and brain isolation. Acute horizontal brain slices (250 μm thick) from the 
midbrain were cut with a vibrating microslicer (Leica VT1200S) in ice-cold oxygenated 
sucrose-based cutting solution containing: NaCl (87 mM), NaHCO3 (25 mM), KCl (2.5 
mM), NaH2PO4 (1.25 mM) sucrose (75 mM), CaCl2 (0.5), MgCl2 (7mM) and glucose (10 
mM) (equilibrated with 95% O2/ 5% CO2). Slices were immediately transferred to a storage 
chamber containing artificial cerebral spinal fluid (ACSF) containing: NaCl (125 mM), 
NaHCO3 (25 mM), KCl (2.5 mM), NaH2PO4 (1.25 mM), MgCl2 (2 mM), CaCl2 (2.5 mM) 
and glucose (11 mM), pH 7.4, constantly bubbled with 95% O2 and 5% CO2; 315-320 
mOsm. Slices were maintained at 35°C in ACSF for 60 min and then kept at room 
temperature before their transfer to the recording chamber. During the recordings, the slices 
were continuously perfused with ACSF at 35.0 ± 2.0°C throughout the experiments. 
Neurons were visualized with a LNScope (Luigs & Neumann, Germany) equipped with an 
oblique illumination condenser, a 60× objective (LUMPplanFI, NA 0.9) and a reflected 
illuminator (Olympus). Slices were illuminated with a collimated LED infrared light source 
(Thorlabs) and wLS LED illumination unit (Q-imaging). The recorded neurons in the VTA 
were identified by their anatomical localization and recorded if they were labeled with red 
retrobeads (or by morphology for recording from non-retrobead labelled cells). Their 
dopaminergic identity was subsequently confirmed by immunohistochemistry. Neuronal 
activity was recorded at the somata with borosilicate glass pipettes (4-6 MΩ) filled with an 
intracellular solution containing: K-gluconate (125 mM), KCl (20 mM), HEPES (10 mM), 
EGTA (10 mM), MgCl2 (2 mM), Na2ATP (2 mM), Na2-phosphocreatine (1 mM), Na3GTP 
(0.3 mM), 0.2% biocytin, pH 7.2 (with KOH); 312.3 mOsm. Electrophysiological recordings 
were obtained using a Multiclamp 700B amplifier and digitized at 10 kHz. Recording of 
spontaneous firing activity in VTA in dopaminergic neurons was achieved in voltage clamp 
cell-attached configuration after formation of a gigaseal.
Baseline activity was recorded during 2 or 3 minutes (sweeps of 5 second duration were 
acquired every 10 seconds) before Oxytocin (1 μM; TOCRIS, # 1910) applied to the 
perfusion reached the recording chamber. Recordings in the presence of Oxytocin were 
continued for 3 minutes. At the end of these recordings, a whole-cell configuration in 
voltage clamp (holding potential: −55 mV) was achieved by disruption of the gigaseal with 
gentle negative pressure applied through the recording pipette. A period of 5 minutes was 
then allowed for loading the neurons with biocytin. Finally, the recording pipette was 
carefully removed and the slice transferred to paraformaldehyde (4 % in PBS) for 
subsequent anatomical analysis. All TH+ cells, including cells negative for retrobeads, were 
used to analyze frequency. Only TH+ and retrobead positive cells recorded for a minimum 
of 3 min after OXT application were used to analyze OXT response, and all data points 
represent an average per minute.
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Ih recordings were performed in whole-cell voltage-clamp configuration after compensating 
the pipette capacitance and the series resistance (Rs) (15-20 MΩ; 40-50%, bandwidth 3.5 
kHz). Rs was monitored on-line and the experiments were discarded if the Rs changed 
>20%.
Neuronal input resistances (Ri) and membrane capacitances were evaluated for each neuron 
by injecting a voltage command of −5 mV for 200 ms duration, from a holding potential 
(HP) of −50 mV. The electrical capacitance of the neurons was determined by fitting a bi-
exponential function to the capacitive current at the beginning of a −50 mV pulse from a 
holding potential of −55 mV (pipette capaciantce was previously compensated during the 
cell-attached configuration prior whole-cell formation). The amplitude-weighted time 
constant (□vc) and measured current peak (Ipeak) amplitude was inserted into the following 
formula to calculate the electrical capacitance.
C[pF ] =
weighted τvc[ms] ∗ Ipeak [pA]
5[mV]
Weighted T_VC was calculated from the the bi-exponential fitting as:
τvc =
A1 ∗ τ1 + A2 ∗ τ2
A1 + A2
Ih was evoked by injecting a series of 1.5 sec duration hyperpolarizing voltage commands 
(Vcomm) from a HP of −50 mV to −130 mV, in consecutive steps of 10 mV. Ih-tail currents 
were evoked at 130 mV at the end of each Vcomm before returning the HP to −50 mV. Ih-tail 
voltage dependency was calculated by plotting their normalized amplitudes. Maximal Ih-tail 
currents (Imax) as defined as recorded after the Vcomm to −130 mV, was set to 1; Minimal 
Ih-tail currents (Imin) as recorded after the HP of −50 mV, was set to 0. A Boltzmann function 
was fitted: I = Imin + (Imax − Imin) / 1 + exp [(V50 − Vcomm)/s]; where V50 is the half-
activation potential and s is the slope factor. After recording the Ih, each cell was switched to 
current clamp mode to record the resting membrane potential. The experimenter was blinded 
to the genotype and treatment condition.
Analysis of mRNA translation
Translational in the VTA was analyzed using FUNCAT55,56, where AHA is incorporated 
into cells and then detected using an alkyne tagged to Alexa 488. Mice were anesthetized at 
P28 and 250 μm thick coronal slices were cut on a vibratome and placed in ACSF for 45 min 
at 35°C to recover. The same cutting solution and ACSF as described for electrophysiology 
was used. Slices were moved to an incubation chamber and incubated for an additional 3h 
with 1mM AHA (Jena Bioscience, CLK-AA005). At the end of incubation, slices were 
transferred to ice-cold 4% PFA and left overnight at 4°C. Next day, slices were incubated for 
1.5h in a blocking solution containing 5% BSA (Sigma), 5% normal donkey serum and 
0.3% Trition X-100 in 1× PBS at agitation at RT. Slices were then washed 3× 5 min 
followed by incubation over night with gentle agitation with 500 μl Click-iT reaction 
cocktail according to the manual instructions (Click-iT Cell Reaction Buffer Kit, Invirogen, 
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C10269). Slices were then washed 3× 10 min with 1xPBS followed by incubation with anti-
TH (Millipor, AB1542, 1:1000) primary antibody at RT for 2h, washed three times in 1× 
PBS, followed by incubation for 2h at room temperature with a secondary antibody. The 
sections were then washed three times in 1× PBS before mounted onto microscope slides 
with ProLong Gold antifade (Invitrogen, p36930). Images were taken on an Olympus 
SpinSR spinning disk with a UPL S APO 30× objective (NA 1.5). All images were taken 
with the same laser power, gain and exposure settings, and analyzed using ImageJ. For 
analysis of AHA incorporation, 10 images were taken of the VTA and the Alexa-488 mean 
fluorescent intensity of 9-20 regions of interest (ROI) corresponding to TH+ somas were 
measured. The mean fluorescent intensity of cells per image was used for analysis, and the 
experimenter was blinded to genotype and treatment. All images within each experiment 
were processed in parallel using identical settings in ImageJ (NIH) and Adobe Photoshop 
CS 8.0 (Adobe systems).
For puromycin incorporation, 400 μm thick coronal slices were cut on a vibratome and 
placed in ACSF (in mM: 125 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 1.25 NaH2PO4, 20 Glucose, 
26 NaHCO3, 95% O2/5% CO2) for 30 min at RT followed by 2h at 32°C. 5 μg/ul puromycin 
(Sigma) was added for 45 min to label newly synthesized proteins. Sections were snap 
frozen and subsequently lysed in 10mM Hepes, 1% SDS, 1mM NaF, 1mM NaVO4 
containing protease and phosphatase inhibitor cocktail (Roche Applied Science), sonicated 
and incubated for 10min at 95°C. Puromycin incorporation was measured by western blot 
(see ‘Western blot’ for detailed methods) using mouse anti-puromycin antibody (EQ0001, 
Kerafast). The results were normalized to signal obtained with anti-calnexin antibodies run 
at the same time on a different blot.
Western blot and AlphaLISA immunoassay
Cortical neurons and brain tissue were homogenized in lysis buffer containing NaCl 137 
mM, KCl, 2.7 mM, Na2HPO4 10 mM, KH2PO4, 1.8 mM, EDTA 5 mM, Triton 1%, and 
complete protease and phosphatase inhibitors (Roche Applied Science). Immunoblotting 
was done with HRP-conjugated secondary antibodies and Pierce ECL Western Blotting 
Substrate. The following primary antibody was used in this study: p-eIF4E (Abcam, 
ab76256 1:1000), eIF4E (Abcam, ab47482 1:1000), p-ERK1/2 (Cell Signaling, 4370S 
1:1000), ERK1/2 (Cell Signaling, 4695S 1:1000), p-eIF4G (Cell Signaling, 2441S 1:1000), 
eIF4G (Cell Signaling, 2498 1:1000), p-MNK1 (Cell Signaling, 2111, 1:1000), MNK1 (Cell 
Signaling, 2195S, 1:1000), GAPDH (Cell Signaling, 5174 1:2000) and calnexin (Stressgen, 
SPA-865 1:2000). Loading controls were run on the same gel, and for some experiments 
Mini PROTEAN® TGX Stain-Free™ Gels (Bio-Rad) were used as loading controls. Signals 
were acquired using an image analyzer (Bio-Rad, ChemiDoc MP Imaging System) and 
images were analyzed and prepared using ImageJ.
For additional measurements of eIF4E phosphorylation state, the AlphaLISA SureFire Ultra 
p-eIF4E (Ser209) Assay Kits (PerkinElmer) were used according to the manufactures 
protocol. AlphaLISA signals were measured using a Tecan SPARK plate reader on 
recommended settings.
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Animals were transcardially perfused with fixative (4% paraformaldehyde in 100mM 
phosphate buffer, pH 7.4) at P26-P32. Brains were post-fixed overnight at 4°C, incubated in 
30% sucrose in 1xPBS for 48h, and snap frozen on dry ice. Tissues were sectioned at 35 μm 
on a cryostat (Microm HM650, Thermo Scientific). Floating sections were kept in 1×PBS 
before incubation with blocking solution containing 0.5% Triton X-100 in 1× TBS and 10% 
normal donkey serum. The slices were incubated with primary antibody at 4°C overnight 
and washed three times in 1× TBS containing 0.5% Triton X-100, followed by incubation 
for 2 hours at room temperature with a secondary antibody. The sections were washed three 
times in 1× TBS containing 0.5% Triton X-100 before mounted onto microscope slides with 
ProLong Gold antifade (Invitrogen, p36930). For post-hoc confirmation of TH positive cells 
after electrophysiology, the sections were fixed in the same fixative as described above, 
washed 3× with 1× PBS before blocking and incubation with anti-TH antibody using same 
method as above. The following primary antibodies were used for this study: sheep anti-TH 
(Millipor, AB1542, 1:1000) and mouse-anti neurophysin-1 (Millipore, MABN844, 1:2000). 
Secondary antibodies used were: donkey anti-sheep IgG-Cy3 (713-165-147), donkey anti-
sheep Cy5 (713-175-147), donkey anti-rabbit IgG Cy3 (711-165-152), goat anti-mouse Cy2 
(714-225-150) all from Jackson ImmunoResearch. Streptavidin DyLight 488 (Thermo 
Scientific #21832, 1mg/ml), was used to visualize biocytin. Hoechst dye was co-applied 
with the secondary antibody at a final concentration of 0.5 μg/ml. Images were acquired on a 
custom-made dual spinning disk microscope (Life Imaging Services GmbH, Basel 
Switzerland) using 10× and 40× objectives. Images were taken bilaterally along the whole 
VTA and PVN dorso-ventral axis and images from at least 4 (VTA) or 5 (PVN) planes were 
analyzed. OXT+ cells in the PVN were counted manually. Neurophysin-1 area coverage and 
puncta intensity was measured using the particle measurement tool in ImageJ on sum 
projections. All images within each experiment were processed in parallel with identical 
settings using ImageJ and Adobe Photoshop CS 8.0 (Adobe systems).
Fluorescent in situ hybridization
Mice were deeply anesthetized using isoflurane inhalation. Brains were quickly removed 
and snap frozen on dry ice prior to storage at −80°C. Brains were cut on a cryostat into 10 
μm sections, adhered to Superfrost ultra plus slides (Thermo Scientific) and stored at −80°C. 
Sections were fixed for 30 min in 4% PFA before being processed using the RNAscope® 
Fluorescent Multiplex Kit (ACD) according to the manufacturers instruction. The following 
probes were used: oxtr (C3 #412171), v1ar (C3 # 418061), th (Slc6a3-C2, #315441) and 
nlgn3 (C1 #497661). Probes were combined as oxtr/th/nlgn3 or v1ar/th/nlgn3. Amp-4-Alt B 
were used for all combinations. Sections were imaged on a custom-made dual spinning disk 
microscope (Life Imaging Services GmbH, Basel Switzerland) using 40× objective, with 12 
section z-stacks with 0.2 um in-between z sections. Images were processed in ImageJ by 
doing sum projection of the z-stacks, followed by analysis of fluorescent intensity and 
number of puncta. Cell types were identified based on the presence of th and DAPI. A region 
of interest (ROI) was drawn around the cell to define the area using DAPI, and only cells 
with no adjacent DAPI staining was used to avoid false positives from signals from a second 
cell. Dots in the ROI were manually counted and fluorescent intensity was analyzed using 
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ImageJ. Images were assembled with identical settings using ImageJ and Adobe Photoshop 
CS 8.0 (Adobe systems).
Cell culture
Cortical cultures were prepared from E16.5 mouse embryos. Neocortices were dissociated 
by addition of papain (130 units, Worthington Biochemical LK003176) for 30 min at 37 °C. 
Cells were maintained in neurobasal medium (Gibco 21103-049) containing 2% B27 
supplement (Gibco 17504-044), 1% Glutamax (Gibco 35050-038), and 1% penicillin/
streptomycin (Sigma P4333). At DIV14, the cells were treated with either vehicle (DMSO) 
or different doses of ETC-168 for 3 hours before harvesting for western blot.
Proteomic analysis
VTA tissue was microdissected from coronal sections using anatomical landmarks. 
Dissected tissue was snap frozen in liquid nitrogen. Successful recovery of proteins from 
dopaminergic neurons was confirmed by quantitative assessment of enrichment of 
dopaminergic markers (dopamine transporter, tyrosine hydroxylase, dopamine 
decarboxylase) as compared to other brain regions (Extended data Fig.4a).
Sample preparation for LC-MS analysis—Tissue was washed twice with PBS and 
dissolved in 50 μl lysis buffer (1% sodium deoxycholate, 0.1M ammoniumbicarbonate), 
reduced with 5mM TCEP for 15 min at 95°C and alkylated with 10mM chloroacetamide for 
30min at 37°C. Samples were digested with trypsin (Promega) at 37°C overnight (protein to 
trypsin ratio: 50:1). To each peptide samples an aliquot of a heavy reference peptide mix 
containing 10 chemically synthesized proteotypic peptides (Spike-Tides, JPT, Berlin, 
Germany) was spiked into each sample at a concentration of 5 fmol of heavy reference 
peptides per 1μg of total endogenous protein mass. Then, the peptides were cleaned up using 
iST cartridges (PreOmics, Munich) according to the manufacturer’s instructions. Samples 
were dried under vacuum and stored at −80 °C until further use.
Targeted PRM-LC-MS analysis of protein isoforms—In a first step, parallel 
reaction-monitoring (PRM) assays57 were generated from a mixture containing 100 fmol of 
each heavy reference peptide and shotgun data-dependent acquisition (DDA) LC-MS/MS 
analysis on a Thermo Orbitrap Fusion Lumos platform (Thermo Fisher Scientific). The 
setup of the μRPLC-MS system was as described previously (Pubmed-ID: 27345528). 
Chromatographic separation of peptides was carried out using an EASY nano-LC 1200 
system (Thermo Fisher Scientific), equipped with a heated RP-HPLC column (75 μm × 30 
cm) packed in-house with 1.9 μm C18 resin (Reprosil-AQ Pur, Dr. Maisch). Peptides were 
analyzed per LC-MS/MS run using a linear gradient ranging from 95% solvent A (0.15% 
formic acid, 2% acetonitrile) and 5% solvent B (98% acetonitrile, 2% water, 0.15% formic 
acid) to 45% solvent B over 60 minutes at a flow rate of 200 nl/min. Mass spectrometry 
analysis was performed on Thermo Orbitrap Fusion Lumos mass spectrometer equipped 
with a nanoelectrospray ion source (both Thermo Fisher Scientific). Each MS1 scan was 
followed by high-collision-dissociation (HCD) of the 10 most abundant precursor ions with 
dynamic exclusion for 20 seconds. Total cycle time was approximately 1 s. For MS1, 1e6 
ions were accumulated in the Orbitrap cell over a maximum time of 100 ms and scanned at a 
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resolution of 120,000 FWHM (at 200 m/z). MS2 scans were acquired at a target setting of 
1e5 ions, accumulation time of 50 ms and a resolution of 30,000 FWHM (at 200 m/z). 
Singly charged ions and ions with unassigned charge state were excluded from triggering 
MS2 events. The normalized collision energy was set to 30%, the mass isolation window 
was set to 1.4 m/z and one microscan was acquired for each spectrum.
The acquired raw-files were database searched against a mouse database (Uniprot, download 
date: 2017/04/18, total of 34,490 entries) by the MaxQuant software (Version 1.0.13.13). 
The search criteria were set as following: full tryptic specificity was required (cleavage after 
lysine or arginine residues); 3 missed cleavages were allowed; carbamidomethylation (C) 
was set as fixed modification; Arg10 (R), Lys8 (K) and oxidation (M) as variable 
modification. The mass tolerance was set to 10 ppm for precursor ions and 0.02 Da for 
fragment ions. The best 6 transitions for each peptide were selected automatically using an 
in-house software tool and imported to Skyline (version 4.1 (https://brendanx-
uw1.gs.washington.edu/labkey/project/home/software/Skyline/begin.view). A mass isolation 
lists containing all selected peptide ion masses were exported form Skyline, split into 8 mass 
lists by charge, c-terminal amino acid and transition and precursor ions. The mass lists were 
then imported into the Lumos operating software for SureQuant analysis using the following 
settings: The resolution of the orbitrap was set to 30k (120k) FWHM (at 200 m/z) for heavy 
(light) peptide ions and the fill time was set to 54 (246) ms, respectively, to reach a target 
value of 1e6 ions. Ion isolation window was set to 0.4 Th and the scan range was set to 
150-1500 Th. The mass window for triggering heavy PRM scans was set to 10 ppm and the 
depended PRM triggering threshold for the light channel was set to a minimum of 2 detected 
transitions. A MS1 scan using the same conditions are for DDA was included in each MS 
cycle. Each condition was analyzed in biological quadruplicates or quintuplicates. All raw-
files were imported into Skyline for protein / peptide quantification. To control for variation 
in sample amounts, the total ion chromatogram (only comprising peptide ions with two or 
more charges) of each sample was determined by Progenesis QI (version 2.0, Waters) and 
used for normalization. A summary of the peptides used is displayed in Supplementary 
Table 1.
Global Proteome analysis using shotgun proteomics—1 μg of peptides of each 
sample were subjected to LC–MS analysis using a using a Q-Exactive HF mass 
spectrometer connected to an electrospray ion source (both Thermo Fisher Scientific) as 
recently specified58 and a custom-made column heater set to 60°C. In brief, peptide 
separation was carried out using an EASY nLC-1000 system (Thermo Fisher Scientific) 
equipped with a RP-HPLC column (75μm × 30cm) packed in-house with C18 resin 
(ReproSil-Pur C18–AQ, 1.9μm resin; Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) 
using a linear gradient from 95% solvent A (0.1% formic acid, 2% acetonitrile) and 5% 
solvent B (98% acetonitrile, 0.1% formic acid) to 45% solvent B over 60 min at a flow rate 
of 0.2μl/min. 3x106 and 105 ions were accumulated for MS1 and MS2, respectively, and 
scanned at a resolution of 60,000 and 15,000 FWHM (at 200 m/z). Fill time was set to 110 
ms for MS1 and 50 ms for MS2 scans. For MS2, a normalized collision energy of 28% was 
employed, the ion isolation window was set to 1.4 Th and the first mass was fixed to 100 Th. 
To determine changes in protein expressions across samples, a MS1 based label-free 
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quantification was carried out. Therefore, the generated raw files were imported into the 
Progenesis QI software (Nonlinear Dynamics, Version 2.0) and analyzed using the default 
parameter settings. MS/MS-data were exported directly from Progenesis QI in mgf format 
and searched against a decoy database of the forward and reverse sequences of the predicted 
proteome from mus musculus (Uniprot, download date: 2017/04/18, total of 34,490 entries) 
using MASCOT (version 2.4.1). The search criteria were set as following: full tryptic 
specificity was required (cleavage after lysine or arginine residues); 3 missed cleavages were 
allowed; carbamidomethylation (C) was set as fixed modification; oxidation (M) as variable 
modification. The mass tolerance was set to 10 ppm for precursor ions and 0.02 Da for 
fragment ions. Results from the database search were imported into Progenesis QI and the 
final peptide measurement list containing the peak areas of all identified peptides, 
respectively, was exported. This list was further processed and statically analyzed using our 
in-house developed SafeQuant R script (SafeQuant, https://github.com/eahrne/SafeQuant 
58). The peptide and protein false discovery rate (FDR) was set to 1% using the number of 
reverse hits in the dataset. All quantitative analyses were performed in biological 
quintuplicates. Proteins with less than 1 peptide were excluded from the analysis.
The results details of the proteomics experiments carried out including identification scores, 
number of peptides quantified, normalized (by sum of all peak intensities) peak intensities, 
log2 ratios, coefficients of variations and p-values for each quantified protein. A summary is 
displayed in Supplementary table 2.
Global Proteome analysis using tandem mass tags—Sample aliquots (prepared as 
described above) containing 10 μg of peptides were dried and labeled with tandem mass 
isobaric tags (TMTpro 16-plex, Thermo Fisher Scientific) according to the manufacturer’s 
instructions. To control for ratio distortion during quantification, a peptide calibration 
mixture consisting of six digested standard proteins mixed in different amounts were added 
to each sample before TMT labeling as recently described58. After pooling the differentially 
TMT labeled peptide samples, peptides were again desalted on C18 reversed-phase spin 
columns according to the manufacturer’s instructions (Macrospin, Harvard Apparatus) and 
dried under vacuum. TMT-labeled peptides were fractionated by high-pH reversed phase 
separation using a XBridge Peptide BEH C18 column (3,5 μm, 130 Å, 1 mm × 150 mm, 
Waters) on an Agilent 1260 Infinity HPLC system. Peptides were loaded on column in 
buffer A (ammonium formate (20 mM, pH 10) in water) and eluted using a two-step linear 
gradient starting from 2% to 10% in 5 minutes and then to 50% (v/v) buffer B (90% 
acetonitrile / 10% ammonium formate (20 mM, pH 10) over 55 minutes at a flow rate of 42 
μl/min. Elution of peptides was monitored with a UV detector (215 nm, 254 nm). A total of 
36 fractions were collected, pooled into 12 fractions using a post-concatenation strategy as 
previously described59, dried under vacuum.
1μg of peptides were LC-MS analyzed as described previously58. Chromatographic 
separation of peptides was carried out using an EASY nano-LC 1000 system (Thermo Fisher 
Scientific), equipped with a heated RP-HPLC column (75 μm × 37 cm) packed in-house 
with 1.9 μm C18 resin (Reprosil-AQ Pur, Dr. Maisch). Aliquots of 1 μg total peptides were 
analyzed per LC-MS/MS run using a linear gradient ranging from 95% solvent A (0.15% 
formic acid, 2% acetonitrile) and 5% solvent B (98% acetonitrile, 2% water, 0.15% formic 
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acid) to 30% solvent B over 90 minutes at a flow rate of 200 nl/min. Mass spectrometry 
analysis was performed on Q-Exactive HF mass spectrometer equipped with a 
nanoelectrospray ion source (both Thermo Fisher Scientific). Each MS1 scan was followed 
by high-collision-dissociation (HCD) of the 10 most abundant precursor ions with dynamic 
exclusion for 20 seconds. Total cycle time was approximately 1 s. For MS1, 3e6 ions were 
accumulated in the Orbitrap cell over a maximum time of 100 ms and scanned at a 
resolution of 120,000 FWHM (at 200 m/z). MS2 scans were acquired at a target setting of 
1e5 ions, accumulation time of 100 ms and a resolution of 30,000 FWHM (at 200 m/z). 
Singly charged ions and ions with unassigned charge state were excluded from triggering 
MS2 events. The normalized collision energy was set to 35%, the mass isolation window 
was set to 1.1 m/z and one microscan was acquired for each spectrum.
The acquired raw-files were searched against a protein database containing sequences of the 
predicted SwissProt entries of mus musculus (www.ebi.ac.uk, release date 2019/03/27), the 
six calibration mix proteins58 and commonly observed contaminants (in total 17,412 
sequences) using the SpectroMine software (Biognosys, version 1.0.20235.13.16424) and 
the TMT 16-plex default settings. In brief, the precursor ion tolerance was set to 10 ppm and 
fragment ion tolerance was set to 0.02 Da. The search criteria were set as follows: full 
tryptic specificity was required (cleavage after lysine or arginine residues unless followed by 
proline), 3 missed cleavages were allowed, carbamidomethylation (C), TMTpro (K and 
peptide n-terminus) were set as fixed modification and oxidation (M) as a variable 
modification. The false identification rate was set to 1% by the software based on the 
number of decoy hits. Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. Proteins sharing significant peptide evidence were grouped into clusters. 
Acquired reporter ion intensities in the experiments were employed for automated 
quantification and statically analysis using a modified version of our in-house developed 
SafeQuant R script (v2.3, ref.58). This analysis included adjustment of reporter ion 
intensities, global data normalization by equalizing the total reporter ion intensity across all 
channels, summation of reporter ion intensities per protein and channel, calculation of 
protein abundance ratios and testing for differential abundance using empirical Bayes 
moderated t-statistics. Finally, the calculated p-values were corrected for multiple testing 
using the Benjamini−Hochberg method. A summary is displayed in Supplementary Table 3.
Raw MS data associated with the manuscript have been deposited in to the 
ProteomeXchange Consortium via the PRIDE60 partner repository with the dataset identifier 
PXD018808 and 10.6019/PXD018808.
Gene ontology, network and gene set enrichment analysis
Gene ontology (GO) analysis was performed using DAVID classification system (https://
david.ncifcrf.gov). Proteins significantly different between vehicle treated wild type and 
Nlgn3 KO (P<0.05) were compared to all proteins detected in the proteomic screen using the 
GO GOTERM_BP_DIRECT annotation data set with minimum number of hits set to 5 and 
maximum P-value threshold to 0.05 with Benjamini correction (P<0.05). Network analysis 
was obtained using String v11 database61. Each node represents a protein altered in 
Hörnberg et al. Page 15













Nlgn3KO VTA compared to wild type VTA in vehicle treated conditions, and each edge 
show protein-protein interaction as determined by experiments and databases. The highest 
confidence (0.900) was used for interaction scores. Disconnected nodes and networks 
containing >6 proteins were removed. Gene set enrichment analysis for TMT proteomic data 
was performed using all proteins detected with at least 2 peptides with PSEA-Quant45. The 
list of GO terms with a Q-value of Q<0.01 were summarized using REVIGO62 with small 
(0.5) allowed similarity, and displayed using Cytoscape.
Statistical analysis
The animals were randomly assigned to each group the moment of drug treatment, and 
minimum 3 independent cohorts were used for behavioral experiments. Statistical analysis 
was conducted with GraphPad Prism 8 (San Diego, CA, USA). The normality of sample 
distributions was assessed and when violated non-parametrical tests were used. When 
normally distributed, the data were analyzed with unpaired t-test for comparison between 
two groups, while for multiple comparisons one-way ANOVA and repeated measures (RM) 
ANOVA were used. For the analysis of variance with 2 factors (two-way ANOVA, RM two-
way ANOVA and RM two-way ANOVA by both factors), normality of sample distribution 
was assumed, and followed by Bonferroni post-hoc test. Differences in frequency 
distribution was assessed using the Kolmogorov-Smirnov test. All the statistical tests 
adopted were two-sided. When comparing two samples distributions similarity of variances 
was assumed, therefore no corrections were adopted. Outliers were identified using ROUTS 
test on the most stringent setting (Q=0.1%). Data are represented as the mean ± s.e.m. and 
the significance was set at P<0.05.
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Extended Data Fig. 1. Loss of social recognition in Nlgn3KO mice.
a-b, Mean social interaction time and data for individual mice in the social habituation/
recognition test plotted for (a) wild type (n=11) and (b) Nlgn3KO mice (n=12). c,d, Mean 
social interaction time and data for individual mice plotted for (c) DATCre control mice 
(n=10) and (d) DATCre::Nlgn3KO mice (n=11). e, Example for validation of targeted gene 
knockdown (n=8 mice) from AAV2-DIO-miRNL3-GFP viruses (green) in TH-positive cells 
(red) in the VTA of DATCre mice. f, Quantification of percentage of TH-positive cells in 
VTA and SNc of DATCre mice that express GFP from the AAV2-DIO-miR-GFP vector 
(n=8). g, h, Mean social interaction time and data for individual mice plotted for control 
mice (g, VTA::DA-miR, n=10) and VTA DA-specific Nlgn3 loss-of-function (h, VTA::DA-
NL3, n=8) in the social habituation/recognition test. g, Mean social interaction time and data 
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for individual mice plotted for (i) vehicle (n=12) and (j) OXTR-A treated mice (n=11). All 
error bars are s.e.m. RM one-way ANOVA followed by Bonferroni’s post-hoc test for 
planned multiple comparison for a, b, c, g, h, i, j; Friedman test followed by Dunn’s post-
hoc test for planned multiple comparison for d. See Supplementary information for 
additional statistics.
Extended Data Fig. 2. Properties of NAc projecting VTA DA neurons in wild type and Nlgn3KO 
mice.
(a) Representative Ih currents recorded from wild type (black) and Nlgn3KO (blue) neurons 
evoked by consecutive hyperpolarizing voltage steps of −10 mV from −50 to −130 mV 
(bottom panel). At the end of each voltage step the voltage command was returned to −130 
mV to evoke tail currents (Ih-tail, depicted with an arrowhead). Red lines show fit of a single 
exponential function used to assess the Ih activation kinetics. (b) Averaged Ih amplitudes 
were plotted against the voltage step. Ih current amplitudes were measured at the steady state 
(indicated with • in a) and the leak current values, as defined as the amplitude of the 
instantaneous currents at the onset of voltage steps (indicated with an * in a), subtracted. (c) 
Voltage-dependency of Ih-tail currents. Ih-tail amplitudes were normalized relative to Ih-tail at 
– 50 mV and −130 mV. Solid lines show fits with a Boltzmann function for least square fit. 
P-value on graph show difference in V50 between datasets. (d) Activation kinetics of the Ih 
as determined by the τ values obtained from the exponential fitting, as a function of the 
voltage commands voltage. Only the values obtained from commands between −130 mV to 
−90 mV were evaluated. (e) Comparison between groups of the resting membrane potential 
as assessed with current clamp recordings. (f) Membrane capacitance (Cm) of wild type and 
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Nlgn3KO DA neurons. (g) Input resistant values (Rin) for wild type and Nlgn3KO.Cm and Ri 
values were obtained in voltage clamp mode by applying a −5 mV (200 ms) voltage 
command from a holding potential set at −50 mV. All error bars are s.e.m. P-value on graph 
represent genotype difference. n=5 mice per genotype, numbers on graphs represent cells. 
RM two-way ANOVA for b; Boltzmann sigmoidal for c; Mixed-effects model for d; 
unpaired two-sided t-test for e, f; two-sided Mann-Whitney test for g. See Supplementary 
information for additional statistics.
Extended Data Fig. 3. Oxytocinergic innervation to VTA and vasopressin receptor 1a mRNA 
levels are not affected in Nlgn3KO mice.
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a, Representative images from 3 mice per genotype of neurophysin 1 (green), a cleavage 
product of the oxytocin neuropeptide precursor that is transported in vesicles together with 
oxytocin63, and TH (red) immunofluorescence in the VTA of wild type and Nlgn3KO mice. 
Note that oxytocinergic axons arise from multiple hypothalamic nuclei, including the 
paraventricular nucleus. b, Mean VTA area coverage and c, puncta fluorescence in the VTA 
from wild type and Nlgn3KO mice. n= 3 mice per genotype. Number in brackets represent 
sections. d, Quantification of mean th intensity per TH+ cell. e, Quantification of Nlgn3 
puncta per 100um2 TH+ cell. f, Quantification of Oxtr puncta per 100um2 TH+ cell. n=WT: 
280 cells from 4 mice; Nlgn3KO: 265 cells from 3 mice for d, e, f. g, targeted proteomic 
(PRM) measurements for oxytocin receptor (left) and vasopressin receptor 1A (right) 
proteins in VTA. Number on bars indicate mice. h, Representative images of FISH labeling 
of avrp1a (cyan), th (red) and Nlgn3 (green) in the VTA from wild type and Nlgn3KO mice. 
Experiment was repeated independently twice. i, Quantification of mean avpr1a intensity per 
TH+ cell. j, Quantification of avpr1a puncta per 100um2 TH+ cell from wild type and 
Nlgn3KO VTA. n: wild type=169 cells from 4 animals; Nlgn3 KO=200 cells from 3 animals 
for i and j. All error bars are s.e.m. Unpaired two-sided t-test for b, c, g; two-sided Mann-
Whitney U test for d, e, f, i, j. See Supplementary information for additional statistics.
Hörnberg et al. Page 20













Extended Data Fig. 4. Ribosomal proteins and translation processes are altered in Nlgn3KO mice.
a, TMT proteomics: graphs plotting abundance of dopamine markers and synaptic proteins 
from VTA, cortex and hippocampus. Dopaminergic markers are strongly enriched in VTA 
samples. n= 5 animals per brain region. b, c, Proteomic analysis of wild type and Nlgn3KO 
VTA, n=5 mice per genotype. b, Enrichment of GO terms for biological processes for 
proteins significantly altered (P<0.05) in Nlgn3KO mice compared to wild type. c, Network-
based analysis of proteins altered in Nlgn3KO VTA (P<0.01). Blue nodes indicate 
downregulated proteins, red nodes upregulated proteins, light blue lines indicate interactions 
known from database and purple lines interactions experimentally determined. Disconnected 
nodes and nodes containing less than 6 proteins are not shown. See methods for additional 
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information of statistics and analysis parameters. d, Mean puromycin incorporation in acute 
cortical slices from adult wild type and Nlgn3KO mice. All error bars are s.e.m. Two-sided 
Mann-Whitney U test for d. See Supplementary information for additional statistics.
Extended Data Fig. 5. Pharmacological profile of novel MNK1/2 inhibitor ETC-168
a, b, Quantification of (a) p-ERK1/2 and (b) p-eIF4G levels compared to non-
phosphorylated protein in cortical neurons at DIV14 treated with ETC-168. n=8 replicates 
from 3 independent experiments. c-d, Quantification of (c) eIF4E (d) ERK1/2 and (e) eIF4G 
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levels normalized to calnexin in cortical neurons at DIV14 treated with ETC-168. One-way 
ANOVA. n=8 replicates from 3 independent experiments. f, Representative western blot of 
cerebellar lysate from wild type mice treated with vehicle or ETC-168 and quantification of 
p-eIF4E levels compared to eIF4E. n: vehicle=4; 1 mg/kg=3; 5 mg/kg=6. g, Representative 
western blot of VTA lysate from wild type mice and Nlgn3KO mice (n=7 mice per 
genotype). h, Quantification of p-eIF4E compared to eIF4E and eIF4E levels in VTA of wild 
type mice and Nlgn3KO mice. n= 7 mice per genotype. i, Normalized p-eIF4E AlphaLisa 
counts from wild type and Nlgn3KO VTA lysate. n= 7 mice per genotype. j, k, 
Representative western blot (j) and quantification (k) of p-MNK1 and MNK1 levels in VTA 
lysate from wild type mice and Nlgn3KO mice. n= 7 mice per genotype. l, Normalized p-
eIF4E AlphaLisa counts from VTA from wild type treated with 5mg/kg ETC-168 for 24h 
+2h. n= 5 mice per genotype. All error bars are s.e.m. One-way ANOVA for a, c, d, e, f; 
Kruskal-Wallis test for b; Unpaired two-sided t-test for h, k; two-sided Mann-Whitney test 
for i, l. See Supplementary information for additional statistics.
Extended Data Fig. 6. ETC-168 treatment restores cognitive rigidity in Fmr1KO mice.
a, Schematics of the Place-independent cue discrimination and reversal task. This task was 
chosen given that phenotypes in cognitive rigidity tasks have been replicated in multiple 
studies on this model. b, Mean consecutive correct responses plotted for Fmr1WT/y and 
Fmr1KO/y mice. c, Treatment schedule of Fmr1WT/y and Fmr1KO /y mice. Animals were 
treated daily with vehicle during the learning phase and with 5 mg/kg ETC-168 during the 
reversal phase 2 hours before the start of the test. d, Mean consecutive correct responses 
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plotted for vehicle treated Fmr1WT /y and vehicle or ETC-168 Fmr1KO/y mice. Numbers in 
brackets indicate mice. Error bars report s.e.m. RM two-way ANOVA followed by 
Bonferrroni’s post-hoc test for b, d. See Supplementary information for additional statistics.
Extended Data Fig. 7. Effect of ETC-168 treatment on protein abundance in wild type and 
Nlgn3KO mice.
a, Experimental outline. b, Representative western blot and quantification of p-eIF4E 
compared to eIF4E levels in VTA lysate from wild type mice treated with vehicle or 5mg/kg 
ETC-168 for 7 consecutive days. n: vehicle=6; ETC-168: 7. c, Normalized p-eIF4E 
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AlphaLisa counts from wild type mice VTA treated with vehicle or 5mg/kg ETC-168 for 7 
consecutive days. n: vehicle=6; ETC-168: 7. d, Graphs plotting TMT proteomic normalized 
protein expression of dopaminergic markers in VTA from vehicle or ETC-168 treated wild 
type and Nlgn3KO mice. Animals were treated for 7 days. n=4 mice per genotype and 
treatment. e,f, Graphical representation of Molecular function GO terms enriched in (e) 
Nlgn3KO versus wild type vehicle treated and (f) Nlgn3KO ETC-168 versus wild type 
vehicle treated VTA. GO terms were summarized using REVIGO and only terms with 
Q<0.01 are represented. g,h, TMT proteomic comparison of VTA from (g) vehicle-treated 
mice and (h) ETC-168 treated Nlgn3KO versus wild type. Relative frequency of log2 fold 
change in core proteasome n abundance (Nlgn3KO/wild type) is plotted. n= 4 mice per 
genotype and treatment. All error bars are s.e.m. Unpaired two-sided t-test for b; two-sided 
Mann-Whitney U test for c. Kolmogorov-Smirnov test for g, h. See methods and 
Supplementary information for additional statistics.
Extended Data Fig. 8. Effect of short-term ETC-168 treatment on social recognition in wild type 
and Nlgn3KO mice.
a-d, Time course of time interacting in the social habituation/recognition test for mice after 
short-term treatment with ETC-168. (a) Wild type vehicle (n=12), (b) wild type ETC-168 
(n=10), (c) Nlgn3KO vehicle (n=9), and (d) Nlgn3KO ETC-168 (n=11). Error bars report 
s.e.m. Friedmans test followed by Dunn’s post hoc test for planned multiple comparison for 
a, c, d, RM one-way ANOVA followed by Bonferroni’s post-hoc test for planned multiple 
comparison for b. See Supplementary information for additional statistics.
Hörnberg et al. Page 25













Extended Data Fig. 9. Effect of ETC-168 treatment is dependent on the oxytocin receptor.
a, Experimental outline. b, Mean social interaction time in Nlgn3KO mice treated with 5 
mg/kg ETC-168 and either vehicle or 10 mg/kg OXTR-A. Number in brackets indicate 
mice. c, Social recognition index for Nlgn3KO mice treated with ETC-168 and vehicle, or 
ETC-168 and OXTR-A. Number on graph indicate mice. d-e, Individual values and mean of 
time interacting in the social habituation/recognition test after treatment with (d) ETC-168 + 
vehicle (n=9), or (e) ETC-168 + OXTR-A (n=8). Error bars report s.e.m. RM two-way 
ANOVA followed by Bonferroni’s post-hoc test for b; unpaired two-sided t-test for c; RM 
one-way ANOVA followed by Bonferroni’s post-hoc test for planned multiple comparison 
for d, e. See Supplementary information for additional statistics.
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Extended Data Fig. 10. Effect of long-term ETC-168 treatment on behavior in wild type and 
Nlgn3KO mice.
a, Experimental schematics of chronic ETC-168 treatment and behavior schedule. Number 
of animals per treatment conditions for all behaviors in b-p: wild type vehicle=9, wild type 
ETC-168=10, Nlgn3KO vehicle=8, Nlgn3KO ETC-168=9. b, c, Mean social interaction time 
in (b) wild type and (c) Nlgn3KO mice treated for 8 days with vehicle or 5 mg/kg ETC-168. 
d, Social recognition index for wild type and Nlgn3KO mice treated with vehicle or 5 mg/kg 
ETC-168. Numbers in brackets indicate mice. e-f, Individual values and mean time 
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interacting in the social habituation/recognition test after chronic treatment with ETC-168 
for (e) wild type vehicle (n=9), (f) wild type ETC-168 (n=10), (g) Nlgn3KO vehicle (n=8), 
and (h) Nlgn3KO ETC-168 (n=9). i, Experimental schematics of object habituation/
recognition test in juvenile mice. j-l, Mean object interaction time plotted for (j) wild type 
and (k) Nlgn3KO mice. P-value above graphs report Trial. l, Object recognition index. m, 
Mean velocity (cm/sec) in an open field arena during 7 min. n, Time spend in center of the 
open field arena. o, Number of marbles buried during a 30 minutes marble burying test. p, 
Percentage weight gain in wild type and Nlgn3KO mice treated with ETC-168 or vehicle. P-
value for treatment is displayed on graphs. Error bars report s.e.m. RM two-way ANOVA 
followed by Bonferroni’s post-hoc test for genotype and treatment for b, c, j, k; RM two-
way ANOVA followed by Bonferroni’s post-hoc test for genotype and treatment for d, l, o; 
Friedman test followed by Dunn’s post-hoc test for planned multiple comparison for e, f, h; 
One-way ANOVA followed by Bonferroni’s post-hoc test for planned multiple comparison 
for g; RM two-way ANOVA for m, n, p. See Supplementary information for additional 
statistics.
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Fig. 1. Oxytocin response is altered in VTA DA neurons lacking Nlgn3.
a, 5-trial social habituation/recognition task. s1=first, s2=second social stimulus. b,c, Mean 
social interaction time (b) and social recognition index (c) in wild type and Nlgn3KO mice. 
Numbers on graphs represent mice. d, Nlgn3KO mutation containing a loxP-flanked 
transcriptional stop cassette. In DATCre mice Nlgn3 is selectively re-expressed in 
dopaminergic neurons. e,f, Mean social interaction time (e) and social recognition index (f) 
in DATCre and DATCre::Nlgn3KO mice. g, VTA AAV-injection in DAT-Cre mice for 
microRNA-mediated knockdown of Nlgn3 in VTA-DA neurons (VTA::DA-NL3). h,i, Mean 
social interaction (h) and social recognition index (i) for VTA::DA-NL3 or control 
(VTA::DA-miR) mice. j, Oxytocin receptor antagonist treatment (OXTR-A, L-368,899 10 
mg/kg i.p. in saline). k,l Mean social interaction (k) and social recognition index (l) for 
OXTR-A and vehicle treated mice. m, Retrobeads were injected in the NAc medial shell and 
tissues prepared for slice physiology. n, Retrobead injection site in the NAc (top) and TH 
immunoreactivity and retrobead labeling in biocytin-filled VTA neurons (bottom) after 
recording. o, Example traces of spontaneous firing at baseline (top) and after bath 
application of 1 μM OXT (bottom) in VTA DA neurons from wild type (left) and Nlgn3 KO 
(right). p, Frequency at baseline in TH-positive wild type and Nlgn3 KO VTA DA neurons. 
n: wild type=22 cells from 12 animals; Nlgn3 KO=14 neurons from 8 animals. q, Average 
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firing frequency (Hz) after bath application with OXT in retrobead-labeled TH-positive cells 
in VTA of wild type and Nlgn3KO mice. P-value on graph: Within group comparison of 
baseline vs. OXT 3rd min. n: wild type= 8 cells from 7 animals; Nlgn3 KO=10 neurons from 
7 animals. Error bars are s.e.m. RM two-way ANOVA followed by Bonferroni’s post-hoc 
test for b, e, h, k, q; unpaired two-sided t-test for c, f, i, p; two-sided Mann-Whitney test for 
l. Additional statistics in Supplementary Information.
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Fig. 2. Disruption of translational regulation in VTA of Nlgn3KO mice.
a, Representative image of OXT (red) and DAPI (blue) immunofluorescence in the PVN of 
wild type and Nlgn3KO mice. b, Mean OXT positive cells per section in the PVN in wild 
type and Nlgn3KO mice. n= 3 mice per genotype, numbers on bar indicate sections analyzed. 
c, Representative fluorescent in situ hybridization (FISH) images in the VTA from wild type 
(top) and Nlgn3KO (bottom) using probes for th (red), nlgn3 (green) and oxtr (magenta). d, 
Quantification of mean fluorescence intensity per th+ cell from wild type and Nlgn3 KO 
VTA for nlgn3 (left) and oxtr (right). n: wild type= 280 cells from 4 animals; Nlgn3 KO=265 
cells from 3 animals. e, Scheme for AHA incorporation on slice preparations from untreated 
and vehicle treated mice. f, Representative images of acute slice measurements of protein 
synthesis in VTA visualized by AHA incorporation (green) with marking of TH-positive 
cells (red). g, quantitative assessment of AHA incorporation in naïve mice versus mice 
treated by oral gavage with vehicle. n: wild type untreated= 3 animals; Nlgn3KO untreated, 
Nlgn3KO vehicle and wild type vehicle = 4 animals. Numbers on graph refer to the number 
of images analyzed (8-20 VTA DA cells per image, approximately 10 images per animal). 
All error bars are s.e.m. Two-sided Mann-Whitney test for b, d; Kruskal-Wallis test followed 
by Dunn’s multiple comparison test for g. See Supplementary information for additional 
statistics.
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Fig. 3. The novel MNK1/2 inhibitor ETC-168 rescues translation in Nlgn3KO VTA.
a, ETC-168 targets MNK1/2. Note that eIF4E phosphorylation decreases affinity of eIF4E 
for the mRNA 5’cap structure b, eIF4E phosphorylation in day in vitro 14 cortical neurons 
treated with ETC-168 for 3 hours. n=8 replicates, 3 independent experiments. c, 
Representative western blot and quantification of VTA lysate from wild type mice treated 
with vehicle or 5 mg/kg ETC-168. Numbers on graphs represent mice. d, Pharmacokinetic 
analysis of ETC-168 in male mice (n=27) after single oral dose of 10 mg/kg. Plasma levels 
in red, brain levels in blue. Half life (T1/2), maximal concentration (Cmax), and brain to 
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plasma exposure (AUCratio) are displayed on the graph. e, Tandem mass tag (TMT) 
proteomic comparison of VTA from vehicle-treated mice (n=4 mice per genotype and 
treatment). Relative frequency of log2 fold change in either all detected proteins, cytosolic, 
or mitochondrial ribosomal protein abundance is plotted (Nlgn3KO/wild type). f, 
Comparison as in e for log2 fold change in protein abundance in ETC-168 treated Nlgn3KO 
versus wild type. g, FUNCAT assay in acute slices from vehicle or ETC-168 treated mice 
(5mg/kg or vehicle by oral gavage). h, Representative examples of AHA incorporation 
(green) in TH-positive cells (red). i, Quantitative assessment of AHA incorporation in 
vehicle (as in Fig. 2h for comparison to untreated mice) versus ETC-168 treated wild type 
and Nlgn3KO mice. n=4 mice per genotype and treatment. Numbers on graphs refer are 
number of images analyzed. Error bars are s.e.m. One-way ANOVA followed by 
Bonferroni’s post-hoc test for b; two-sided unpaired t-test for c; Kolmogorov-Smirnov test 
for e, f; Kruskal-Wallis test followed by Dunn’s multiple comparison test for i. Additional 
statistics in Supplementary Information.
Hörnberg et al. Page 36













Fig. 4. MNK inhibition restores social novelty responses in Nlgn3 KO mice.
a, Scheme for drug treatment and analysis. b, Firing frequency at baseline in VTA DA 
neurons from Nlgn3 KO animals untreated, treated with vehicle, or 5 mg/kg ETC-168. n: 
untreated=14 neurons from 8 mice; vehicle=8 neurons from 4 mice; ETC-168=14 neurons 
from 8 mice. The wild type mouse data from Fig. 1c is presented for comparison (n=22). c, 
OXT-induced frequency changes over time in VTA DA neurons from Nlgn3 KO animals 
treated with vehicle or 5 mg/kg ETC-168. Wild type mice from Fig. 1e are presented for 
comparison. P-values on graph: Baseline vs. OXT 3rd min. n: vehicle treated=8 cells from 4 
mice; ETC-168 treated=11 neurons from 6 mice. d, e, Mean social interaction time in (d) 
wild type and (e) Nlgn3KO mice treated with vehicle or 5 mg/kg ETC-168. f, Social 
recognition index for wild type and Nlgn3KO mice treated with vehicle or 5 mg/kg ETC-168. 
Numbers in brackets indicate mice. All error bars are s.e.m. One-way ANOVA followed by 
Bonferroni’s post-hoc test for b; RM two-way ANOVA followed by Bonferroni’s post-hoc 
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test for c; RM two-way ANOVA between all genotype and treatment groups followed by 
Bonferroni’s post-hoc test for d, e; RM two-way ANOVA followed by Bonferroni’s post-hoc 
test for treatment and genotype for f. Additional statistics Supplementary Information.
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